Research progress in the role of gut microbiota in the pathogenesis and treatment of IgA nephropathy

doi:10.3969/j.issn.1674-8115.2023.08.013

Abstract

Abstract:

As the most common form of glomerulonephritis worldwide, IgA nephropathy (IgAN) is characterized by the diffuse deposition of immune complexes formed by glycosylation-deficient IgA1 (Gd-IgA1) and its specific antibodies (Gd-IgA1-IgG) in the glomerular mesangium. Although the mechanisms of Gd-IgA1 production are still unknown, there is accumulating evidence that Gd-IgA1-producing plasma cells are primarily derived from gut-associated lymphoid tissue, giving rise to the "gut-kidney axis" theory. Further research has discovered that gut microbiota may be involved in IgAN development and progression, and that several interventions to regulate gut microbiota, such as probiotics, fecal microbiota transplantation, and intestinal immunity modulation, may be used in the treatment of IgAN. In patients with IgAN, targeted-release formulation-budesonide has been shown to reduce urinary protein levels and delay kidney progression. Gut microbiota has promising potential as a preventive, diagnostic and therapeutic target for IgAN, and further research is needed.

Key words: IgA nephropathy, intestinal microbiota, gut-kidney axis, intestinal mucosal immunity, therapeutics

CLC Number:

R692.3

LI Junru, OUYANG Yan, XIE Jingyuan. Research progress in the role of gut microbiota in the pathogenesis and treatment of IgA nephropathy[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(8): 1044-1048.

TrendMD

References 37

1	BERGER J, HINGLAIS N. Intercapillary deposits of IgA-IgG[J]. J Urol Nephrol (Paris), 1968, 74(9): 694-695.
2	PATTRAPORNPISUT P, AVILA-CASADO C, REICH H N. IgA nephropathy: core curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441.
3	GESUALDO L, DI LEO V, COPPO R. The mucosal immune system and IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 657-668.
4	ISHO B, FLORESCU A, WANG A A, et al. Fantastic IgA plasma cells and where to find them[J]. Immunol Rev, 2021, 303(1): 119-137.
5	OHYAMA Y, RENFROW M B, NOVAK J, et al. Aberrantly glycosylated IgA1 in IgA nephropathy: what we know and what we don't know[J]. J Clin Med, 2021, 10(16): 3467.
6	FLOEGE J, RAUEN T, TANG S C W. Current treatment of IgA nephropathy[J]. Semin Immunopathol, 2021, 43(5): 717-728.
7	YANG Y, PALM N W. Immunoglobulin A and the microbiome[J]. Curr Opin Microbiol, 2020, 56: 89-96.
8	SHAPIRO J M, DE ZOETE M R, PALM N W, et al. Immunoglobulin A targets a unique subset of the microbiota in inflammatory bowel disease[J]. Cell Host Microbe, 2021, 29(1): 83-93.e3.
9	REHNBERG J, SYMRENG A, LUDVIGSSON J F, et al. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: a Swedish population-based cohort study[J]. J Am Soc Nephrol, 2021, 32(2): 411-423.
10	KIRYLUK K, LI Y F, SCOLARI F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens[J]. Nat Genet, 2014, 46(11): 1187-1196.
11	MONTEIRO R C, BERTHELOT L. Role of gut-kidney axis in renal diseases and IgA nephropathy[J]. Curr Opin Gastroenterol, 2021, 37(6): 565-571.
12	SALLUSTIO F, CURCI C, CHAOUL N, et al. High levels of gut-homing immunoglobulin A⁺B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients[J]. Nephrol Dial Transplant, 2021, 36(9): 1765.
13	KANO T, SUZUKI H, MAKITA Y, et al. Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy[J]. Kidney Int, 2021, 100(2): 364-376.
14	FELLSTRÖM B C, BARRATT J, COOK H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial[J]. Lancet, 2017, 389(10084): 2117-2127.
15	SALLUSTIO F, CURCI C, DI LEO V, et al. A new vision of IgA nephropathy: the missing link[J]. Int J Mol Sci, 2019, 21(1): 189.
16	HE J W, ZHOU X J, LI Y F, et al. Associations of genetic variants contributing to gut microbiota composition in immunoglobin A nephropathy[J]. mSystems, 2021, 6(1): e00819-e00820.
17	MONTEIRO R C, RAFEH D, GLEESON P J. Is there a role for gut microbiome dysbiosis in IgA nephropathy?[J]. Microorganisms, 2022, 10(4): 683.
18	LIANG X L, ZHANG S M, ZHANG D F, et al. Metagenomics-based systematic analysis reveals that gut microbiota Gd-IgA1-associated enzymes may play a key role in IgA nephropathy[J]. Front Mol Biosci, 2022, 9: 970723.
19	HAN S S, SHANG L, LU Y, et al. Gut microbiome characteristics in IgA nephropathy: qualitative and quantitative analysis from observational studies[J]. Front Cell Infect Microbiol, 2022, 12: 904401.
20	DE ANGELIS M, MONTEMURNO E, PICCOLO M, et al. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN)[J]. PLoS One, 2014, 9(6): e99006.
21	ZHAO J, BAI M, NING X X, et al. Expansion of Escherichia-shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy[J]. J Am Soc Nephrol, 2022, 33(12): 2276-2292.
22	WU H W, TANG D E, YUN M H, et al. Metabolic dysfunctions of intestinal fatty acids and tryptophan reveal immuno-inflammatory response activation in IgA nephropathy[J]. Front Med (Lausanne), 2022, 9: 811526.
23	ZHENG N Y, FAN J J, WANG B, et al. Expression profile of BAFF in peripheral blood from patients of IgA nephropathy: correlation with clinical features and Streptococcus pyogenes infection[J]. Mol Med Rep, 2017, 15(4): 1925-1935.
24	MONTEIRO R C, SUZUKI Y. Are there animal models of IgA nephropathy?[J]. Semin Immunopathol, 2021, 43(5): 639-648.
25	MCCARTHY D D, KUJAWA J, WILSON C, et al. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy[J]. J Clin Invest, 2011, 121(10): 3991-4002.
26	ZHOU N, SHEN Y, FAN L R, et al. The characteristics of intestinal-barrier damage in rats with IgA nephropathy[J]. Am J Med Sci, 2020, 359(3): 168-176.
27	WANG Y, TIAN L L, SUN L, et al. Gut microbes in immunoglobulin A nephropathy and their potential therapeutic applications[J]. Front Med (Lausanne), 2022, 9: 823267.
28	TAN J X, DONG L Q, JIANG Z, et al. Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling[J]. J Transl Med, 2022, 20(1): 382.
29	ANTUSHEVICH H. Fecal microbiota transplantation in disease therapy[J]. Clin Chim Acta, 2020, 503: 90-98.
30	LAURIERO G, ABBAD L, VACCA M, et al. Fecal microbiota transplantation modulates renal phenotype in the humanized mouse model of IgA nephropathy[J]. Front Immunol, 2021, 12: 694787.
31	ZHAO J, BAI M, YANG X X, et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports[J]. Ren Fail, 2021, 43(1): 928-933.
32	ZHI W Q, SONG W Z, ABDI SAED Y, et al. Fecal capsule as a therapeutic strategy in IgA nephropathy: a brief report[J]. Front Med (Lausanne), 2022, 9: 914250.
33	BARRATT J, LAFAYETTE R A, ROVIN B H, et al. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy[J]. Expert Rev Clin Immunol, 2023, 19(7): 699-710.
34	BARRATT J, LAFAYETTE R, KRISTENSEN J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy[J]. Kidney Int, 2023, 103(2): 391-402.
35	CHEMOUNY J M, GLEESON P J, ABBAD L, et al. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice[J]. Nephrol Dial Transplant, 2019, 34(7): 1135-1144.
36	DI LEO V, GLEESON P J, SALLUSTIO F, et al. Rifaximin as a potential treatment for IgA nephropathy in a humanized mice model[J]. J Pers Med, 2021, 11(4): 309.
37	PAPISTA C, LECHNER S, BEN MKADDEM S, et al. Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction[J]. Kidney Int, 2015, 88(2): 276-285.

[1]	WANG Jieyi, ZHENG Dan, ZHENG Xiaojiao, JIA Wei, ZHAO Aihua. Research progress in biological activities and mechanisms of theabrownin [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 768-774.
[2]	DAI Qin, WANG Weiming. Inflammatory expression in IgA nephropathy cell model and anti-inflammatory effect of sodium valproate [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(6): 751-757.
[3]	DAI Qin1, WANG Wei-ming2. Role of histone acetylation in the pathogenesis of IgA nephropathy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(8): 1063-1068.
[4]	LU Hai-yang, ZHAO Wei-li. Role of gastrointestinal microbiota in tumorigenesis [J]. , 2019, 39(9): 1083-.
[5]	HUANG Yu-xin, TANG Ye-zhou, ZHAO Ya-juan, FU Hao, WANG Yong, JIN Hua. Progress of transcranial direct current stimulation in the treatment of unipolar and bipolar depressive disorders [J]. , 2019, 39(12): 1460-.
[6]	KONG Ling-yun, JIANG Geng-ru. Effect of serum IgA1 on human mesangial cells and of TGF-β1 in patients of IgA nephropathy with different renal function progress [J]. , 2018, 38(6): 647-.
[7]	SHI Ying-feng, XU Liu-qing, ZHUANG Shou-gang, LIU Na . Correlation between pathology and clinical indexes in IgA nephropathy patients#br# [J]. , 2017, 37(10): 1362-.
[8]	YANG Meng, XIE Jing-yuan, OUYANG Yan, ZHANG Xiao-yan, PAN Xiao-xia, XU Jing, WANG Zhao-hui, WANG Wei-ming, CHEN Nan. Analysis of clinicopathologic features and prognosis of IgA nephropathy patients with H factor deposition in renal tissue [J]. , 2016, 36(8): 1144-.
[9]	ZHOU Yue-ling, JIANG Geng-ru. Research progresses of clinical prediction of development of IgA nephropathy towards end-stage renal disease [J]. , 2016, 36(2): 296-.
[10]	GU Yu, LIU Shuang, ZHU Yi, et al. Establishment and identification of a mice model of transgenic IgA nephropathy [J]. , 2016, 36(1): 43-.
[11]	HUANG Wei, WANG Wei-ming. Applications and research progresses of new immunosuppressive agents for the treatment of IgA nephropathy [J]. , 2015, 35(11): 1722-.
[12]	WANG Wei-ming, JIA Xiao-yuan, PAN Xiao-xia, et al. Clinical study on treatment of IgA nephropathy with renal insufficiency by corticosteroid, corticosteroid combined with cyclophosphamide and corticosteroid combined with mycophenolate mofetil [J]. , 2013, 33(2): 162-.
[13]	JIA Xiao-yuan, WANG Wei-ming. Advances in treatment of IgA nephropathy [J]. , 2012, 32(3): 361-.
[14]	ZHANG Li-ping, XING Ling-ling, PEI Hua-ying, et al. Relationship between insulin resistance and renal tubulointerstitial lesion in IgA nephropathy [J]. , 2010, 30(4): 441-.